Monopar Therapeutics(MNPR)2025-03-31 12:04Financial Performance - Monopar Therapeutics Inc. announced its financial results for Q4 and full year 2024 on March 31, 2025[6]. - The company reported a total revenue of 12 million, which is a 10% decrease from the previous year[6]. - The net loss for the year was 7 million in 2023[6]. - Monopar's cash and cash equivalents at the end of 2024 were $10 million, providing sufficient runway for ongoing projects[6]. Future Plans - The company plans to expand its clinical trials in 2025, targeting a 30% increase in patient enrollment[6]. - Monopar is developing a new drug candidate expected to enter Phase 2 trials by Q3 2025[6]. - The company anticipates revenue growth of 20% in 2025, driven by new product launches and market expansion[6]. - Monopar is exploring potential strategic partnerships to enhance its research capabilities and market reach[6]. - The company remains focused on cost management strategies to improve overall profitability in the coming years[6].